Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Hematology

Living Well: Monitoring, Safety, and Quality of Life

At a Glance

Living with Indolent Systemic Mastocytosis (ISM) requires long-term monitoring of tryptase levels and bone density, alongside proactive safety measures. Patients must coordinate with specialists before surgeries to avoid triggers and always carry two epinephrine auto-injectors for severe reactions.

Living with Indolent Systemic Mastocytosis (ISM) is a journey of long-term partnership with your medical team. Because this is a chronic but typically stable condition, your “job” is to monitor for changes while maintaining your quality of life [1][2].

Your Long-Term Monitoring Schedule

To ensure your ISM remains “indolent,” your doctor will likely follow a regular monitoring routine. While the exact frequency depends on your symptoms, the standard approach includes:

  • Blood Work (Every 6–12 Months): Checking your serum tryptase level is the most common way to track the “activity” of your mast cells [3]. Significant or rapid increases can sometimes signal a change in the disease [4].
  • KIT VAF Monitoring: Your doctor may measure your Variant Allele Frequency (VAF)—a percentage that tells you how many of your cells carry the KIT mutation [5]. A stable VAF is a reassuring sign of disease stability [6].
  • Bone Density (DEXA) Scans: Because mast cells can weaken bones, you should have a baseline DEXA scan, usually followed by repeat scans every 2 years, to monitor for osteoporosis or thinning bones [7][8].
  • Physical Exams: Regular checks for an enlarged liver or spleen (hepatosplenomegaly), which are signs of increased mast cell burden [9][3].

Surgery and Anesthesia: Staying Safe

One of the most important things you can do for your long-term safety is to communicate your diagnosis before any medical procedure. Surgery and anesthesia can trigger mast cells to release dangerous amounts of chemicals [10][11].

  • Pre-medication: It is standard for ISM patients to “pre-medicate” before surgery with high-dose H1 and H2 antihistamines to create a safety net against reactions [12][11].
  • “Safe” vs. “Trigger” Drugs: While triggers vary by person, some anesthetics and medications are known to be higher risk. For example, NSAIDs can be dangerous triggers for some patients but essential treatments for others. Do not experiment on your own; always clear medications with an allergist or hematologist familiar with ISM before surgery [13][14]. Always have your hematologist coordinate directly with your anesthesiologist before any procedure [15].

Managing Anaphylaxis Risk

Because ISM makes your mast cells “twitchy,” you are at a higher risk for anaphylaxis (a severe, life-threatening allergic reaction) [16][17].

  • Epinephrine is Non-negotiable: You should always carry two epinephrine auto-injectors (like an EpiPen). This is a firm medical recommendation due to the risk of “biphasic” (recurring) reactions, device malfunction, or needing a second dose before paramedics arrive [18].
  • Medical ID: Wear a medical alert bracelet that clearly states “Systemic Mastocytosis.” In an emergency, this informs paramedics that your reaction may be more complex than a standard allergy [19].
  • Emergency Action Plan: Work with your doctor to create a written Emergency Action Plan. Critical Rule: Antihistamines cannot stop anaphylaxis. You must use your epinephrine auto-injector first for severe reactions. Never attempt to ‘wait it out’ with pills. Print this plan and bring it directly to the Emergency Room, as many ER doctors may not be familiar with systemic mastocytosis [11].

Navigating the Emotional Impact

Living with a rare disease involves unique psychological challenges. It is normal to feel “scan-xiety” (anxiety before tests) or fear about when the next reaction might occur [20].

  • Uncertainty: Because symptoms can be unpredictable, many patients feel a loss of control [21].
  • Validation: Recognize that your symptoms—including fatigue and “brain fog”—are real and driven by the biology of your condition [22]. Seeking support from specialized mast cell patient advocacy groups can significantly reduce the feeling of isolation [23].

Common questions in this guide

How often should my tryptase levels be checked with ISM?
Your doctor will likely check your serum tryptase levels every 6 to 12 months. This routine blood work helps track the activity of your mast cells and ensures your condition remains stable.
What is KIT VAF monitoring?
KIT Variant Allele Frequency (VAF) monitoring measures the percentage of your cells that carry the KIT mutation. Keeping this percentage stable is a reassuring sign that your indolent systemic mastocytosis is not progressing.
Why do I need a DEXA scan if I have systemic mastocytosis?
Mast cells can weaken your bones over time, increasing your risk for osteoporosis. You should have a baseline DEXA scan, usually followed by repeat scans every two years, to monitor your bone density.
Do I need to do anything special before having surgery with ISM?
Yes, surgery and anesthesia can trigger a severe mast cell reaction. It is standard to pre-medicate with high-dose antihistamines and have your hematologist coordinate directly with your anesthesiologist to ensure safe medications are used.
Why do I need to carry two epinephrine auto-injectors?
Indolent systemic mastocytosis puts you at a higher risk for severe anaphylaxis. Carrying two injectors is necessary in case the device malfunctions, you experience a recurring reaction, or you need a second dose before paramedics arrive.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific 'Variant Allele Frequency' (VAF) of my KIT D816V mutation, and how often will we monitor this percentage to check for stability?
  2. 2.Can you provide me with a 'surgical pre-medication protocol' that I can give to any anesthesiologist or surgeon I might see in the future?
  3. 3.Based on my current tryptase and bone marrow burden, what is my specific risk for anaphylaxis, and should I be carrying more than two epinephrine auto-injectors?
  4. 4.How often should I have a DEXA scan, and are there specific bone-strengthening vitamins or medications I should be taking proactively?
  5. 5.Are there any specific vaccines (like live vaccines) or medications that you want me to avoid entirely based on my history?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Systemic Mastocytosis: The Difficult Patient with a Rare Disease. Case Presentation and Brief Review.

    Desmond DH, Carmichael MG

    Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health 2018; (77(2)):27-29.

    PMID: 29435387
  2. 2

    Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches.

    Paiva ML, Yumeen S, Saliba E, DiMarco C

    JAAD case reports 2023; (36()):63-66 doi:10.1016/j.jdcr.2023.04.009.

    PMID: 37250010
  3. 3

    Review and Updates on Systemic Mastocytosis and Related Entities.

    Li JY, Ryder CB, Zhang H, et al.

    Cancers 2023; (15(23)) doi:10.3390/cancers15235626.

    PMID: 38067330
  4. 4

    Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis.

    Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, et al.

    Blood 2019; (134(5)):456-468 doi:10.1182/blood.2018886507.

    PMID: 31151985
  5. 5

    Accurate Diagnosis and Prognosis in Systemic Mastocytosis: The Role of Mutational Analysis.

    Weiler CR, Akin C

    The journal of allergy and clinical immunology. In practice 2020; (8(9)):3128-3129 doi:10.1016/j.jaip.2020.06.030.

    PMID: 33039016
  6. 6

    Correlates of organ damage in patients with advanced systemic mastocytosis enrolled in clinical trials of avapritinib.

    Liang EC, Perkins C, Lu R, et al.

    Blood neoplasia 2025; (2(4)):100127 doi:10.1016/j.bneo.2025.100127.

    PMID: 41424934
  7. 7

    Bone Disease in Mastocytosis.

    Orsolini G, Viapiana O, Rossini M, et al.

    Immunology and allergy clinics of North America 2018; (38(3)):443-454 doi:10.1016/j.iac.2018.04.013.

    PMID: 30007462
  8. 8

    Endocrine manifestations of systemic mastocytosis in bone.

    Greene LW, Asadipooya K, Corradi PF, Akin C

    Reviews in endocrine & metabolic disorders 2016; (17(3)):419-431 doi:10.1007/s11154-016-9362-3.

    PMID: 27239674
  9. 9

    Routine abdominal ultrasonography has limited value in the care for patients with indolent systemic mastocytosis.

    de Mol CL, Hermans MAW, Gerth van Wijk R, et al.

    Hematology (Amsterdam, Netherlands) 2017; (22(9)):544-547 doi:10.1080/10245332.2017.1324377.

    PMID: 28486845
  10. 10

    Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.

    Castells M, Butterfield J

    The journal of allergy and clinical immunology. In practice 2019; (7(4)):1097-1106 doi:10.1016/j.jaip.2019.02.002.

    PMID: 30961835
  11. 11

    NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.

    Gotlib J, Gerds AT, Abdelmessieh P, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(2 D)).

    PMID: 38862005
  12. 12

    Management of Mastocytosis and Mast Cell Activation in Children.

    Carter MC, Lange M, Alvarez-Twose I, et al.

    The journal of allergy and clinical immunology. In practice 2026; (14(1)):30-42 doi:10.1016/j.jaip.2025.11.016.

    PMID: 41285204
  13. 13

    Mast Cell Disorders In Drug Hypersensitivity.

    Bonadonna P, Bonifacio M, Zanotti R

    Current pharmaceutical design 2016; (22(45)):6862-6869 doi:10.2174/1381612822666160928121857.

    PMID: 27779084
  14. 14

    [Anaphylaxis as part of a clinical diagnosis of mastocytosi - case demonstration].

    Stobiecki M, Sacha M, Czarnobilska E

    Przeglad lekarski 2015; (72(12)):783-6.

    PMID: 27024961
  15. 15

    Insights in Anaphylaxis and Clonal Mast Cell Disorders.

    González-de-Olano D, Álvarez-Twose I

    Frontiers in immunology 2017; (8()):792 doi:10.3389/fimmu.2017.00792.

    PMID: 28740494
  16. 16

    [Vulvar oedema revealing systemic mastocytosis].

    Deveza E, Locatelli F, Girardin M, et al.

    Annales de dermatologie et de venereologie 2015; (142(11)):685-9.

    PMID: 26003033
  17. 17

    Pathogenesis and Pathology of Mastocytosis.

    Metcalfe DD, Mekori YA

    Annual review of pathology 2017; (12()):487-514 doi:10.1146/annurev-pathol-052016-100312.

    PMID: 28135563
  18. 18

    Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab.

    Weiss SL, Hyman JB, Carlson GS, Coop CA

    Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2021; (38(1)):44-48 doi:10.12788/fp.0081.

    PMID: 33574649
  19. 19

    Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.

    Valent P, Akin C, Gleixner KV, et al.

    International journal of molecular sciences 2019; (20(12)) doi:10.3390/ijms20122976.

    PMID: 31216696
  20. 20

    Living with systemic mastocytosis: Balancing between vulnerability and resilience: A qualitative study.

    Levedahl KH, Nilsson A, Ungerstedt J, Hedström M

    European journal of oncology nursing : the official journal of European Oncology Nursing Society 2022; (60()):102172 doi:10.1016/j.ejon.2022.102172.

    PMID: 35963124
  21. 21

    Lifetime Disability-Adjusted Life-Year Assessment of Indolent Systemic Mastocytosis.

    Mounié M, Burel HD, Molinier L, et al.

    The journal of allergy and clinical immunology. In practice 2025; (13(4)):923-929 doi:10.1016/j.jaip.2024.12.034.

    PMID: 39746514
  22. 22

    Altered leukocyte subsets and immune proteome indicate proinflammatory mechanisms in mastocytosis.

    Hermans MAW, Heeringa JJ, Swagemakers SGA, et al.

    The Journal of allergy and clinical immunology 2022; (150(1)):146-156.e10 doi:10.1016/j.jaci.2021.12.786.

    PMID: 35026208
  23. 23

    Health-Related Quality of Life and Influencing Factors in Adults with Nonadvanced Mastocytosis-A Cross-Sectional Study and Qualitative Approach.

    Pulfer S, Ziehfreund S, Gebhard J, et al.

    The journal of allergy and clinical immunology. In practice 2021; (9(8)):3166-3175.e2 doi:10.1016/j.jaip.2021.04.059.

    PMID: 33965596

This page provides general safety and monitoring guidelines for living with indolent systemic mastocytosis. Always consult your hematologist or allergist before surgeries or changing your anaphylaxis emergency plan.

Get notified when new evidence is published on Indolent systemic mastocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.